GHRP-2 Mechanism of Action

Introduction

GHRP-2 (pralmorelin) is a synthetic hexapeptide that acts as a full agonist at the growth hormone secretagogue receptor subtype 1a (GHS-R1a), the G protein-coupled receptor identified as the molecular target for both synthetic GHSs and the endogenous hormone ghrelin. Published research has characterized the intracellular signaling cascade initiated by GHS-R1a activation, the sites of action within the hypothalamic-pituitary axis, and a number of ancillary molecular interactions beyond GH secretion. This article summarizes the published mechanistic evidence, with appropriate attribution to the primary literature.

Receptor Target and Pathway

GHS-R1a: Cloning and Characterization

The molecular target of GHRP-2 was identified in 1996 by Howard and colleagues, who cloned a novel orphan G protein-coupled receptor (GPCR) from human and swine tissue. The receptor — designated GHS-R1a — was found to mediate the GH-releasing activity of synthetic GHSs including GHRP-2. The authors characterized GHS-R1a as a 364-amino acid seven-transmembrane domain receptor coupling primarily to the Gq/11 family of G proteins and activating the phospholipase C (PLC) signaling pathway upon agonist binding [1]. This landmark publication provided the molecular framework within which GHRP-2's pharmacology has been understood ever since.

The discovery that GHS-R1a was an orphan receptor at the time of its cloning prompted a search for its endogenous ligand. In 1999, Kojima and colleagues isolated ghrelin from rat stomach extracts — a 28-amino acid acylated peptide produced primarily in the gastric fundus — and demonstrated it was the cognate endogenous ligand for GHS-R1a [2]. This discovery established that synthetic GHRPs, including GHRP-2, had been acting as pharmacological mimics of an endogenous hormonal system, substantially deepening the scientific context for the compound class.

Receptor Distribution

GHS-R1a is expressed at high levels on somatotroph cells of the anterior pituitary gland and on neurons of the hypothalamic arcuate nucleus. Research reported that GHRP-2 and related compounds exerted GH-releasing activity at both sites, producing effects on pituitary GH release directly and on hypothalamic signaling relevant to GH secretory regulation [3].

Reported Molecular Interactions

Primary Gq/11-PLC-IP3 Cascade

Published mechanistic studies established that GHS-R1a activation by GHRP-2 triggers coupling to Gq/11 proteins, which in turn activates phospholipase C beta (PLCβ). PLCβ hydrolyzes membrane phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).

IP3 binds to IP3 receptors on the endoplasmic reticulum membrane, triggering rapid release of calcium from intracellular stores. The resulting transient rise in cytosolic calcium concentration within somatotroph cells activates calcium-calmodulin-dependent kinases and promotes exocytosis of GH-containing secretory granules. This mechanism was characterized as the primary pathway coupling GHS-R1a activation to acute GH release [1].

Synergy with GHRH

Arvat and colleagues reported in a 1997 human study that GH responses produced by GHRP-2 substantially exceeded the response to maximal-dose GHRH administered alone. A similar synergistic relationship between GHS-R1a agonists and GHRH has been documented for the related compound hexarelin. The authors noted that this supraadditive response was consistent with data indicating that endogenous GHRH is required for GHRPs to reach their full GH-releasing potential, and that the two signaling systems — GHS-R1a and GHRH receptor — interact at multiple levels of the hypothalamic-pituitary axis [4]. This synergy is among the most pharmacologically significant features of the compound class and has informed GH axis research design across multiple subsequent studies.

Modulation of Somatostatinergic Tone

Evidence from preclinical studies indicated that GHRPs exerted an additional functional effect by reducing the inhibitory influence of somatostatin — also termed somatotropin release-inhibiting factor (SRIF) — on pituitary GH secretion. Research in rats reported that the GH-releasing activity of KP-102 (GHRP-2) was comparatively less sensitive to suppression by endogenous somatostatin than the GH response to exogenous GHRH, suggesting a differential interaction with somatostatinergic tone at the pituitary level [3].

Beta-Arrestin Pathway

Beyond the primary Gq/11 cascade, published research identified a secondary signaling arm involving beta-arrestins. Studies on GHS-R1a signaling characterized a late-phase pathway in which beta-arrestin recruitment following receptor activation led to Akt (protein kinase B) phosphorylation through a G protein-independent mechanism [1]. This branch of receptor signaling has been studied in the context of GHS-R1a's constitutive activity and the receptor's pleiotropic effects in various tissue types.

Downstream Effects Reported in Research

Pituitary Hormones Beyond GH

Arvat and colleagues' 1997 comparative study in healthy human volunteers reported that GHRP-2 administration produced stimulation of prolactin (PRL), ACTH, and cortisol secretion in addition to GH release. The prolactin response was lower than that produced by TRH, while the ACTH and cortisol responses were comparable to those produced by human corticotropin-releasing hormone (hCRH). The authors characterized these as pharmacological properties shared across the GHRP class, attributable to GHS-R1a expression in tissue outside the somatotroph lineage, including corticotroph cells and hypothalamic regions relevant to the HPA axis [4].

Orexigenic Signaling

Laferrère and colleagues reported in a 2005 human study published in The Journal of Clinical Endocrinology & Metabolism that intravenous infusion of GHRP-2 in lean healthy male volunteers was associated with a measured increase in ad libitum food intake compared with saline infusion. The authors noted that this observation was consistent with the known orexigenic properties of ghrelin acting through GHS-R1a, and characterized GHRP-2 as a tool for investigating ghrelin-mediated appetite signaling in humans [5]. This orexigenic property is shared across the GHS-R1a agonist class, including the selective secretagogue ipamorelin.

Antinociceptive Effects in Animal Models

Zeng and colleagues reported in a 2014 study published in Peptides that GHRP-2 administration in mice produced antinociceptive (pain-attenuating) effects at the supraspinal level. The authors reported that this effect was attenuated by prior administration of the opioid receptor antagonist naloxone, indicating that GHRP-2 antinociception was mediated in part through activation of the endogenous opioid system. The authors described GHRP-2 as a pharmacological tool for investigating interactions between the GHS-R1a system and opioid nociceptive circuits [6].

Vascular Research in Preclinical Models

Titterington and colleagues (2009) reported in Endocrinology that chronic GHRP-2 administration to apolipoprotein E-deficient (ApoE−/−) mice was associated with reduced indices of vascular superoxide production. The authors' findings in that specific model informed subsequent investigations into the cardiovascular biology of the GHRP class, with Berlanga-Acosta and colleagues' 2017 review characterizing the broader literature on cytoprotective observations across synthetic GHRPs [8].

Active Research Frontiers

Several aspects of GHRP-2's mechanism represent productive areas of ongoing investigation.

High-resolution structural biology of GHS-R1a in complex with GHRP-2 remains an open question. As cryo-EM methods advance, such data would clarify the molecular determinants distinguishing GHRP-2's binding profile from other GHS compounds and from ghrelin itself.

The relative contributions of hypothalamic versus direct pituitary action to GHRP-2's GH-releasing activity in humans remain under inquiry. Preclinical studies in median eminence-lesioned rats reported substantially attenuated but not abolished GH responses, suggesting both direct pituitary action and hypothalamic amplification are engaged [3].

The GH-independent cytoprotective effects reported for the broader GHRP class — cardioprotective and anti-apoptotic observations in preclinical models — continue to be investigated, with mechanistic dependency on GHS-R1a versus CD36 versus other targets representing active lines of inquiry [7]. Researchers interested in the full published-study landscape for GHRP-2 can consult the companion GHRP-2 published research article, and GHRP-2 from SpartaLabs is available for research use with batch-specific Certificates of Analysis.

References

1. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–977. PMID: 8688086. DOI: 10.1126/science.273.5277.974

2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. PMID: 10604470. DOI: 10.1038/45230

3. Arase K, Ohboshi T, Endo S, Akahane S. Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):857–867. PMID: 15646370. DOI: 10.1055/s-0031-1297041

4. Arvat E, Di Vito L, Maccario M, Broglio F, Boghen MF, Deghenghi R, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885–891. PMID: 9285939. DOI: 10.1016/s0196-9781(97)00016-8

5. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611–614. PMID: 15699539. DOI: 10.1210/jc.2004-1585

6. Zeng P, Li S, Zheng Y, Liu FY, Wang J, Zhang D, Wei J. Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice. Peptides. 2014;55:103–109. PMID: 24657737. DOI: 10.1016/j.peptides.2014.02.013

7. Titterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE−/− mice but does not reduce atherosclerosis. Endocrinology. 2009;150(12):5478–5487. PMID: 19819949. PMC: PMC2795722. DOI: 10.1210/en.2009-0283

8. Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D, Mendoza-Marí Y, Rodríguez-Ulloa A, García-Ojalvo A, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Endocrinol Diabetes. 2017;10:1179546817694558. PMID: 28469490. PMC: PMC5392015. DOI: 10.1177/1179546817694558